Surgical Robotics Technology
Inspira™ Technologies OXY B.H.N. Ltd. has announced the integration of a next-generation oxygenation indicator into its AI-powered HYLA™ blood sensor technology, designed to enable the rapid detection of critical oxygen-related conditions without the need for intermittent blood draws.
We believe that the integration of this advanced indicator represents a significant enhancement in critical care monitoring. The technology is designed to provide data through real-time and continuous monitoring of oxygenation therapy, enabling the rapid detection of tissue hypoxia and the early warning of respiratory complications. The advanced AI-powered system is designed to indicate the level of lung function and to monitor vital blood parameters, positioning HYLA as a potential game-changer in the $2.5 billion point-of-care testing and arterial blood gas analyzer market.
Clinical validation of the enhanced HYLA blood sensor, with its new oxygenation indicator, is currently underway at Sheba Medical Center, ranked among the world’s top 10 smart hospitals by Newsweek. The Company is optimistic about the ongoing evaluations and expects to share preliminary clinical results in the near future. The non-invasive technology utilizes sophisticated optical sensors and machine-learning algorithms to deliver continuous monitoring of blood parameters and oxygen levels, with a U.S. Food and Drug Administration (“FDA”) submission for regulatory clearance anticipated for the second half of 2025.
“This advancement marks an important step in transforming critical care monitoring,” said Dagi Ben-Noon, chief executive officer of Inspira. “The integration of this new oxygenation indicator into HYLA will enable healthcare providers to monitor and respond to changes in tissue oxygenation in real-time. We continue to advance in our clinical evaluation program and look forward to sharing preliminary clinical results with the public in the near future, which we hope will further validate the HYLA’s unique technological offering and superiority over traditional blood sensors in the market.”
The addition of advanced oxygenation monitoring capabilities further strengthens HYLA’s position as a comprehensive blood monitoring solution. When combined with the FDA-cleared INSPIRA ART100 system, this technology aims to provide a more complete approach to patient care by enabling continuous, non-invasive monitoring while maintaining consciousness during treatment.
Source: Inspira Technologies
